Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Gynecologic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Rectal Neoplasms 2Hand-Foot Syndrome 1Colonic Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Trastuzumab 4Psychiatric Rehabilitation 3cediranib 2Watchful Waiting 2Therapeutics 2Radiotherapy 2Interleukin-12 Subunit p35 2Interleukin-12 2Docetaxel 2Capecitabine 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 2tipifarnib 1sargramostim 1palbociclib 1orantinib 1montanide ISA 51 1entinostat 1denileukin diftitox 1X-Ray Therapy 1Thalidomide 1Taxes 1Standard of Care 1Pyridoxine 1Propranolol 1Physical Therapy Modalities 1Phlebotomy 1Pemetrexed 1Paclitaxel 1N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 1Microscopy, Electron 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms, Male × Pyridoxine × Gastrointestinal × Clear all
NCT00559858 2013-08-02

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
270 enrolled
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Breast Neoplasms, Male, Hand-Foot Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡